Last reviewed · How we verify
bolus+infusion
A bolus-infusion regimen delivers a rapid initial dose followed by continuous or repeated slower administration to achieve and maintain therapeutic drug levels.
At a glance
| Generic name | bolus+infusion |
|---|---|
| Sponsor | Università degli Studi di Ferrara |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Bolus-infusion dosing strategies are used across many drug classes to quickly reach effective concentrations (bolus phase) while minimizing toxicity, then sustain those levels through controlled infusion. This approach is particularly common in critical care, chemotherapy, and antimicrobial therapy where rapid onset combined with steady-state maintenance is clinically advantageous.
Approved indications
Common side effects
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction (PHASE2)
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- The Impact of OliPhenolia® Supplementation on Exercise Induced Inflammation and Functional Movement in Humans. (NA)
- Biofeedback as an Adjunctive Treatment for Post-stroke Dysphagia (NA)
- Canadian Critical Care Comparative Effectiveness Platform (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bolus+infusion CI brief — competitive landscape report
- bolus+infusion updates RSS · CI watch RSS
- Università degli Studi di Ferrara portfolio CI